Cancer News

Comparison of Aromatase Inhibitors Expands Treatment Options for Women Requiring Hormonal Therapy for Early Stage Breast Cancer (04/19/2018)

CancerConnect News: According to an Italian research team the three aromatase inhibitors approved for the treatment of postmenopausal hormone receptor–positive early stage breast cancer have no significant differences in effectiveness or safety, For the study, 3697 postsurgical patients with invasive hormone receptor–positive breast cancer were enrolled from 76 Italian public healthcare institutions between March 9, …

Continue reading "Comparison of Aromatase Inhibitors Expands Treatment Options for Women Requiring Hormonal Therapy for Early Stage Breast Cancer"

FDA Approves Perjecta for Adjuvant Treatment of HER2-positive Breast Cancer (03/26/2018)

CancerConnect News: On December 20, 2017, the Food and Drug Administration granted regular approval to Perjeta (pertuzumab) for use in combination with Herceptin (trastuzumab) and chemotherapy as adjuvant treatment of patients with HER2-positive early stage breast cancer at high risk of recurrence. About Perjeta Breast cancer is the second leading cause of cancer-related death among …

Continue reading "FDA Approves Perjecta for Adjuvant Treatment of HER2-positive Breast Cancer"

At-home Genetic Testing may be Convenient, but it isn’t Complete (03/20/2018)

March 14, 2018 https://www.statnews.com/2018/03/14/genetic-testing-23andme-brca/   Home delivery for everything from fresh produce to custom-selected clothing has become a way of life for many Americans. While most home-delivery conveniences are generally changing our lives for the better — giving us more time and choices — at-home genetics kits that reveal information about the risk of developing …

Continue reading "At-home Genetic Testing may be Convenient, but it isn’t Complete"

FDA Approval for Verzenio™ as Initial Treatment for Advanced Breast Cancer (03/12/2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. About VerzenioTM Verzenio is an inhibitor of cyclin-dependent kinases …

Continue reading "FDA Approval for Verzenio™ as Initial Treatment for Advanced Breast Cancer"

Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast Cancer (02/21/2018)

A clinically relevant “liquid biopsy” test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer (TNBC), according to new research published by a multi-institutional team of researchers.1,2 Although TNBC represents just 10-15 percent of all breast diagnoses, the disease is responsible for 35 …

Continue reading "Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast Cancer"

Kisqali Combination Promising for Pre-menopausal Hormone Receptor Positive Breast Cancer (02/13/2018)

CancerConnect News: The CDK4/6 inhibitor Kisqali (ribociclib) has been given breakthrough status by the US Food and Drug Administration as an initial endocrine-based treatment for of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor. Results from …

Continue reading "Kisqali Combination Promising for Pre-menopausal Hormone Receptor Positive Breast Cancer"

Five Common Sign & Symptoms of Breast Cancer (02/12/2018)

CancerConnect News: Breast cancer is a cancer that originates in the area of the breast, where cells replicate too quickly, causing a tumor. Breast cancer is most common in women, but I can also occur in men. Breast cancer is caused by an abnormality that is genetic, but only a very low percentage of such …

Continue reading "Five Common Sign & Symptoms of Breast Cancer"

Breast Cancer Treatments May Increase Risk of Heart Disease (02/05/2018)

American Heart Association Scientific Statement Statement Highlights: Some breast cancer therapies can damage the heart and healthcare providers should carefully monitor breast cancer treatment effects on the heart. Breast cancer survivors, especially older women, are more likely to die from cardiovascular diseases such as heart failure rather than breast cancer. Breast cancer patients may be …

Continue reading "Breast Cancer Treatments May Increase Risk of Heart Disease"

Lynparza Slows Spread of Inherited Breast Cancer Caused by BRCA Mutations: First Drug Approved for BRCA Breast Cancer (01/15/2018)

CancerConnect News: The US Food and Drug Administration (FDA) has extended the approval of Lynparza (olaparib) to include the treatment of metastatic breast cancer in patients who carry the specific inherited BRCA mutation.  These patients can be identified by using the FDA-approved genetic test, BRACAnalysis CDx (Myriad Genetic Laboratories). About BRCA Breast Cancer Breast cancer …

Continue reading "Lynparza Slows Spread of Inherited Breast Cancer Caused by BRCA Mutations: First Drug Approved for BRCA Breast Cancer"

Updated Keytruda®/Halaven® Report Encouraging for Treatment of Triple Negative Breast Cancer (01/10/2018)

CancerConnect News: The investigative treatment combination including Keytruda® (pembrolizumab) plus Halaven® (eribulin) could provide a potential therapeutic option for patients with advanced triple-negative breast cancer (TNBC) whose disease has advanced following prior therapies. Results of this treatment combination were initially presented at the 2016 annual San Antonio Breast Cancer Symposium (SABCS) and just updated at …

Continue reading "Updated Keytruda®/Halaven® Report Encouraging for Treatment of Triple Negative Breast Cancer"